Montevideo.-A study developed by Uruguayan and American scientists supported the efficacy of a new drug recommended to treat chronic lymphoid leukemia (CLL) after an investigation showed that the drug could increase mutations of the tumor cell. According to Efe, the head of the LLC Laboratory of the Pasteur Institute of Montevideo, Pablo Oppezzo, the study, prepared by the Uruguayan center in collaboration with the MD Anderson cancer Center of Texas (United States), “reinsured” the effectiveness Of the Ibrutinib drug, which should be taken for life to treat the disease. Oppezzo said that while the Ibrutinib was already approved by the U.S. Food and Drug Administration (FDA) and is in the guidelines for treatment of this type of cancer worldwide, a study of 2017 put a “red light” on the use of Fármac Or to fight the LLC. The scientist pointed out that this study, from Nature magazine, says that the use of drugs such as Ibrutinib, recommended to treat LLC in patients who do not respond to standard treatment, increases the expression of the enzyme AID, which causes mutations in the DNA and , in excess, can benefit the tumor cells.
Scientists from Uruguay and the U.S. test drug efficacy against leukemia. Illustrative image. Photo: Pixabay
As a result, according to Oppezzo, it emerged from its laboratory, in collaboration with the MD Anderson cancer Center, the idea of studying samples of patients treated with Ibrutinib to corroborate if the expression of the enzyme actually increased with the administration of Drug.
“In this publication of 2017 they had mainly worked with cell lines, not primary cells, i.e. cells extracted from the patient, and that can often be an important difference,” hit the investigator. Taking a little advantage of the fundamental fact that MD Anderson makes clinical trials quite routinely (…) As we had samples of patients treated with Ibrutinib before and throughout the treatment, this allowed us to say ‘ let’s evaluate now how it is The expression of AID ‘, he reaffirmed. In this sense, Oppezzo said that, from the trials, scientists from Uruguay and the United States concluded in the study, published last Thursday in Blood magazine, that Ibrutinib not only does not increase the expression of the enzyme but decreases it, which also ” It is associated with the death of the most proliferating tumour cells. ” This work (…) reassure a little that the treatment will not end up generating an increase in the expression of AID and gives the other interesting fact that it was not described that the Ibrutinib also affects the proliferating populations that are of the populations more necessary in which to make white, “he valued.
LLC primarily affects adults between 60 and 75 years of age. Illustrative image. Photo: Pixabay
On the other hand, the researcher at the Pasteur Institute underscored the importance of scientific collaboration with avant-garde centers such as the MD Anderson Center, where the winner of the Nobel Prize in medicine 2018 Jim Allison plays, because, he said, this many times Allows you to access samples that are not counted. ” Unfortunately here in Uruguay, or in different countries in the region, trials (essays) are not so common, then (…) is very convenient for us in that case to have the collaboration of centers that do, “he said. Anyway, Oppezzo nuanced that reaching such collaborations is not easy and that in the case of the Pasteur Institute was achieved from both works that positioned the center internationally as collaborations with other experts in the area of hematology Within Uruguay. On the other hand, the scientist said that currently more than half of the researchers in his laboratory is involved in projects that seek to investigate the role that the enzyme AID can have in lymphocytes B, which are the immune cells that are seen Affected with cancer. ” One of the hypotheses pursued by my group and I wish that we can demonstrate reliably at some point is that the expression of the enzyme AID in patients leukemic progressors has a fundamental role and that this role is given by mutating the DNA “, Concluded. The LLC primarily affects adults between 60 and 75 years and differs from other types of leukemia because it is heterogeneous, because in some patients the disease does not evolve and others do. In Uruguay the Ibrutinib is one of the drugs that the National Resources Fund included in 2018 to treat this disease.
Original source in Spanish
